Virpax Pharmaceuticals, Inc.

Equities

VRPX

US9282512063

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
4.261 USD +13.03% Intraday chart for Virpax Pharmaceuticals, Inc. +2.93% +33.12%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs MT
Virpax Pharmaceuticals Announces Preliminary Results of Probudurtm Pilot Study with the U.S. Army Institute of Surgical Research CI
Virpax Pharmaceuticals Stockholders Approve Reverse Stock Split Plan; Shares Fall MT
Virpax Pharmaceuticals Announces Leadership Transition CI
Virpax Pharmaceuticals, Inc. Announces CEO Changes CI
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Virpax Pharmaceuticals Announces Envelta Remains on Track for Trial in Humans Following FDA Review CI
Virpax Names Gerald Bruce as CEO of Novvae Pharmaceuticals Unit MT
Novvae Pharmaceuticals Announces Executive Appointments CI
Virpax Forms New Unit Novvae Pharmaceuticals MT
Virpax Pharmaceuticals, Inc Announces the Formation of Novvae? Pharmaceuticals CI
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Virpax Pharmaceuticals, Inc. Files Provisional Patent Application for NSAID Formulation and Method CI
Virpax Pharmaceuticals Files Patent For Envelta Product Candidate MT
Top Premarket Gainers MT
Virpax Pharmaceuticals Names New CFO MT
Virpax Pharmaceuticals, Inc. Announces Executive Changes CI
Virpax Pharmaceuticals, Inc. Announces CFO Changes CI
Virpax Pharmaceuticals, Inc. Appoints Barbara Ruskin as Class I Director CI
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Virpax Pharmaceuticals Announces Appointment of Barbara A. Ruskin to the Board of Directors CI
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Virpax Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt CI
Chart Virpax Pharmaceuticals, Inc.
More charts
Virpax Pharmaceuticals, Inc. is a preclinical-stage pharmaceutical company. The Company is focused on developing novel and drug delivery systems. Its drug-delivery systems and drug-releasing technologies being developed are focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system (CNS) disorders to enhance patients’ quality of life. Its portfolio consists of multiple preclinical stage product candidates: Epoladerm, Probudur, Envelta, PES200, AnQlar and NobrXiol. Probudur is a drug product candidate based on a liposomal delivery system utilizing large multi-vesicular vesicles (LMVVs) encapsulating a high dose of the local anesthetic bupivacaine. PES200 enables the delivery of a metabolically labile peptide drug (Enkephalin) into the brain for post-traumatic stress disorder. NobrXiol is being developed by Nanomerics as an investigational formulation delivered via the nasal route to enhance Cannabidiol transport to the brain.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
4.261 USD
Average target price
20 USD
Spread / Average Target
+369.35%
Consensus
  1. Stock
  2. Equities
  3. Stock Virpax Pharmaceuticals, Inc. - Nasdaq
  4. News Virpax Pharmaceuticals, Inc.
  5. Virpax Pharmaceuticals Picks Altasciences for Knee Osteoarthritis Pain Treatment Study